Oncode Accelerator

Outsmarting cancer
Impacting lives

Accelerating the Development of Cancer Therapies

Cell and Gene Therapy

Leverage Expertise From Leading Centers of Excellence

The Cell and Gene Therapy Workstream brings together different leading Dutch academic centers each with their own expertise in developing cell-based ATMPs. Interested parties are invited to apply for a Demonstrator Project to co-develop their respective cell and gene therapeutic asset within each dedicated facility:

- CAR T (UMC Groningen, UMC Utrecht)
- TIL (Netherlands Cancer Institute)
- TCR-T (Netherlands Cancer Institute, UMC Utrecht)
- Gamma-delta T cells (TEGs) (UMC Utrecht)
- Allogeneic stem cell-derived NK, CAR-NK, Tscm CAR-T (Radboud UMC)

Bridge the Gap From Concept to Clinic

The Oncode Accelerator Cell and Gene Therapy Workstream combines top-notch scientific experience with a multidisciplinary academic infrastructure, to build and optimize robust preclinical pipelines for cell-based Advanced Therapeutic Medicinal Product (ATMP) development.

Innovation Platforms (Patient Cohorts, Organoids and Artificial Intelligence) are integrated to optimize and develop prediction models for the success of ATMP production and clinical effects, with an aim to accelerate the process from target identification to proof-of-concept.

De-risk ATMP Development Using Innovations

Within Demonstrator Projects, patient-derived organoids, in combination with clinical data from our well-defined patient cohorts and artificial intelligence (AI) models, can be applied to optimize and develop prediction models for the success of ATMP production and clinical effects.

By identifying therapeutics and patient groups with the highest likelihood of succeeding in clinical trials, we aim to de-risk and accelerate the process from target identification to proof-of-concept.

Accelerate Product Development Through GMP Simulation

To facilitate rapid translation from the laboratory to the clinic a virtual GMP simulator environment (GMP-sim) is constructed within the Workstream Cell and Gene Therapy.

This GMP-sim creates a pre-GMP environment and consists of a core team of translational scientists and GMP production experts (including pharmacists) with specific focus on bridging the gap between preclinical research and GMP production of ATMPs for clinical application.

Streamline ATMP Development Through Shared Infrastructure

Our infrastructure is shared with the Innovation Center for Advanced Therapies (ICAT), a part of the RegMed XB Pilot Factory. In addition, the BioTherapeutics Unit (BTU) from the Netherlands Cancer Institute is utilized as a second GMP-sim facility, forming part of the infrastructure of the Cell and Gene Therapy Workstream. By connecting and expanding GMP-sim infrastructures within the Netherlands, exploration of new production strategies and quick transition from research-grade production to GMP conditions suitable for patient applications are enabled.

Building Robust Pipelines for the Development of Cell-Based ATMPs

Key to the success of the Oncode Accelerator program is the selection and execution of high-quality Demonstrator Projects which aim to both validate the Oncode Accelerator infrastructure while simultaneously addressing unmet medical needs. New partners who join the Oncode Accelerator Program with a Demonstrator Project to co-develop their oncology ATMP can tap into extensive scientific expertise and plug-and-play models for the development of oncological cell and gene therapies.

Work With Us

Through Oncode Accelerator, we provide academic researchers, biotech drug developers and industry partners with access to expertise, facilities and technologies aimed at efficient, patient-centered development of cancer therapies up to early clinical validation. We are actively seeking ideas for Demonstrator Projects, through which you can access co-funding and support.

Reach out for more information

demonstrators@oncodeaccelerator.nl

About Oncode Accelerator

Oncode Accelerator is a public-private partnership funded by the Dutch National Growth Fund (NGF), which aims to innovate and accelerate the preclinical development of new cancer therapies by placing cancer patients at the core. It is a collaboration between six coordinating partners:

Oncode Accelerator Foundation

Princess Máxima Center pediatric oncology

Netherlands Cancer Institute Antoni van Leeuwenhoek

UMC Utrecht

Leiden University Medical Center

Universiteit Leiden

Get to know us

www.oncodeaccelerator.nl
Oncode Accelerator